Summit Therapeutics Soars on Sarepta Deal
Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.
Summit Therapetuics (SMMT) - Get Report shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics (SRPT) - Get Report . The two companies will develop drugs to treat Duchenne muscular dystrophy. Under the agreement, Summit will get $40 million up front and could receive $522 million in milestone payments. Just last month, Sarepta won approval from the FDA for a drug to treat the disorder.
Employees of TheStreet are restricted from trading individual securities.
